Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K
Tumor Immunotherapy01:27

Tumor Immunotherapy

480
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
480
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.5K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Level and Source of Copper Affects Gene Expression of Copper-Regulatory Proteins and Soluble and Mucosal Copper Concentrations in the Small Intestine of Weanling Pigs.

Animals : an open access journal from MDPI·2026
Same author

MHC Class I and PD-L1 Expression May Predict Treatment Response to Anti-PD-1/PD-L1 Therapy in Metastatic Triple-negative Breast Cancer Patients.

Applied immunohistochemistry & molecular morphology : AIMM·2026
Same author

Resistance to anti-PD-1 immunotherapy for stage III and IV melanoma: a global chart review study.

Journal for immunotherapy of cancer·2026
Same author

Phase I/II clinical trial of a melanoma vaccine targeting shared non-mutated antigens and a shared mutated BRAF neoantigen with an agonistic CD40 antibody (CDX-1140) plus TLR3 agonist (poly-ICLC).

Journal for immunotherapy of cancer·2026
Same author

Allostatic Load Predicts Immune-Related Toxicity and Survival in Melanoma Patients Receiving Immune Checkpoint Inhibitors.

Cancers·2026
Same author

Assessing venous thromboembolism risk in lung cancer: a comprehensive evaluation of the khorana score, clinical characteristics, and incidence of thrombosis.

Frontiers in oncology·2026

Related Experiment Video

Updated: Jun 7, 2025

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

15.7K

Precision Oncology in Melanoma: Changing Practices.

Sean C Dougherty1, William L Flowers2, Elizabeth M Gaughan3

  • 1Division of Hematology/Oncology, Department of Medicine, University of Virginia Health System, Charlottesville, Virginia; and.

Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine
|November 14, 2024
PubMed
Summary

Advances in melanoma treatment, including targeted therapies and immune checkpoint inhibitors, have significantly improved survival rates. Nuclear medicine and personalized treatments like tumor-infiltrating lymphocytes and mRNA vaccines offer future promise for managing malignant melanoma.

Keywords:
focused ultrasoundimmunotherapymelanoma stagingoncologyradioimmunoimagingtargeted therapy

More Related Videos

Author Spotlight: Recreating Melanoma Complexity with Patient-Derived Organoids for Immunotherapy Evaluation
05:33

Author Spotlight: Recreating Melanoma Complexity with Patient-Derived Organoids for Immunotherapy Evaluation

Published on: September 6, 2024

1.3K
A Melanoma Patient-Derived Xenograft Model
07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

12.3K

Related Experiment Videos

Last Updated: Jun 7, 2025

A 3D Organotypic Melanoma Spheroid Skin Model
08:49

A 3D Organotypic Melanoma Spheroid Skin Model

Published on: May 18, 2018

15.7K
Author Spotlight: Recreating Melanoma Complexity with Patient-Derived Organoids for Immunotherapy Evaluation
05:33

Author Spotlight: Recreating Melanoma Complexity with Patient-Derived Organoids for Immunotherapy Evaluation

Published on: September 6, 2024

1.3K
A Melanoma Patient-Derived Xenograft Model
07:07

A Melanoma Patient-Derived Xenograft Model

Published on: May 20, 2019

12.3K

Area of Science:

  • Oncology
  • Immunology
  • Genomics

Background:

  • Malignant melanoma prognosis was historically poor due to limited treatment options.
  • Recent advances have transformed the understanding and treatment of melanoma.

Purpose of the Study:

  • To review the progress in melanoma genomics, tumor immune microenvironment, and immunogenicity.
  • To highlight the impact of novel therapies on patient survival rates.

Main Methods:

  • Analysis of clinical trials on BRAF/MEK inhibition and immune checkpoint inhibitors (PD-1, CTLA-4, LAG-3).
  • Review of personalized therapies such as tumor-infiltrating lymphocytes and mRNA vaccines.
  • Evaluation of advancements in nuclear medicine imaging for staging and treatment response assessment.

Main Results:

  • Combined BRAF/MEK inhibition and immune checkpoint inhibitors have dramatically improved overall survival for metastatic melanoma.
  • Immune checkpoint inhibition is now utilized in neoadjuvant and adjuvant settings.
  • Personalized therapies and advanced nuclear medicine imaging show significant promise.

Conclusions:

  • Therapeutic strategies for malignant melanoma have evolved significantly, leading to improved patient outcomes.
  • Nuclear medicine, incorporating AI and novel tracers, is expected to play an increasing role in melanoma evaluation.
  • Continued research in personalized medicine and advanced imaging will further enhance melanoma management.